Who owns Acrivon Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
Institutional ownership of ACRV from SEC Form 13F filings across 36 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 36 institutions disclosed 7.5M shares of Acrivon Therapeutics, Inc. worth $11.3M — about 18% of shares outstanding; the largest disclosed holder is Sands Capital Alternatives, LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
36
13F holders
$11.3M
value, 2026 filers
18%
of shares outstanding (7.5M sh)
4
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of ACRV's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Sands Capital Alternatives, LLC | 2.3M | $4.1M | 0.7% | 5.5% | +7.9% |
| 2 | ACADIAN ASSET MANAGEMENT LLC | 1.2M | $2,073 | 0.0% | 2.8% | +37.7% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 952,008 | $1.7M | 0.0% | 2.3% | -34.1% |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 888,130 | $1.6M | 0.0% | 2.1% | 0.0% |
| 5 | TWO SIGMA INVESTMENTS, LP | 641,498 | $1.1M | 0.0% | 1.5% | +64.7% |
| 6 | MARSHALL WACE, LLP | 531,856 | $946,704 | 0.0% | 1.3% | -5.1% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 265,241 | $472,273 | 0.0% | 0.6% | +12.2% |
| 8 | BlackRock, Inc. | 239,112 | $425,620 | 0.0% | 0.6% | +14.4% |
| 9 | VANGUARD FIDUCIARY TRUST CO | 184,128 | $327,748 | 0.0% | 0.4% | +71.2% |
| 10 | JANE STREET GROUP, LLC | 74,648 | $132,874 | 0.0% | 0.2% | -68.9% |
| 11 | NORTHERN TRUST CORP | 67,202 | $119,620 | 0.0% | 0.2% | +37.4% |
| 12 | UBS Group AG | 43,850 | $78,053 | 0.0% | 0.1% | +26.6% |
| 13 | CITADEL ADVISORS LLCNEW | 41,276 | $73,471 | 0.0% | 0.1% | new |
| 14 | PRELUDE CAPITAL MANAGEMENT, LLC | 24,015 | $42,747 | 0.0% | 0.1% | 0.0% |
| 15 | BANK OF AMERICA CORP /DE/ | 16,407 | $29,204 | 0.0% | 0% | -0.6% |
| 16 | GOLDMAN SACHS GROUP INC | 14,920 | $26,558 | 0.0% | 0% | +1.2% |
| 17 | Squarepoint Ops LLC | 13,309 | $23,690 | 0.0% | 0% | -51.6% |
| 18 | AAF Wealth Management, LLC | 10,678 | $19,007 | 0.0% | 0% | 0.0% |
| 19 | HRT FINANCIAL LPNEW | 10,316 | $18 | 0.0% | 0% | new |
| 20 | Marex Group Ltd | 10,000 | $17,800 | 0.0% | 0% | -50.0% |
| 21 | FEDERATED HERMES, INC. | 7,924 | $14,105 | 0.0% | 0% | 0.0% |
| 22 | BARCLAYS PLC | 7,354 | $13,090 | 0.0% | 0% | +23.8% |
| 23 | FMR LLC | 6,957 | $12,383 | 0.0% | 0% | -26.2% |
| 24 | MORGAN STANLEY | 5,233 | $9,315 | 0.0% | 0% | -85.7% |
| 25 | Tower Research Capital LLC (TRC) | 1,677 | $2,985 | 0.0% | 0% | -62.9% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.